1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Global Genetic Testing Industry

Global Genetic Testing Industry

  • April 2021
  • 573 pages
  • ID: 2284877
  • Format: PDF
  • Global Industry Analysts


Table of Contents


Timely market intelligence is paramount in these uncertain times!

We launched an impact survey to update this project with timely insights during 2020. Update frequency will depend upon evolving market conditions and executive opinions. Our participants are executives driving strategy, marketing, sales and product management at competitive companies worldwide. All updates during the rest of the year are complimentary to clients!

- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the analysis period 2020 through 2027. While deaths due to communicable diseases are expected to decline, mortality rates of non-communicable diseases is forecast to rise significantly. Non-communicable diseases like cardiovascular diseases and cancer represent the leading cause of death, disability and rising healthcare costs worldwide. Predictive genetic testing has the potential to play a key role in fighting this challenge by identifying genetic changes or mutations linked to diseases before onset of symptoms. This helps in effective management of disease progression and mortality by influencing modifiable risk factors and increasing chances of disease prevention. Conventional physician-initiated genetic testing models are intended for individuals with or at the risk of specific medical conditions. Healthcare professionals decide about these tests and order clinical-grade tests from recognized labs. The approach represents the most popular delivery model for genetic testing. The market also encompasses Direct-to-Consumer (DTC) or the consumer-initiated testing model that doesn’t involve a healthcare provider. Hybrid DTC is another model that involves patient-initiated testing along with the participation of medical professional.
- Companies offering these tests allow consumers to order tests online while closely working with a genetic counselor or physician network for safeguarding ordering as well as delivery of test results. Another model involves delivery of the elective genetic analysis to people through executive health and wellness clinics. Genetic sequencing relies on three approaches including whole-genome sequencing (WGS), targeted panels and whole-exome sequencing (WES). WGS focuses on reading the complete genome that covers more than 3.3 billion DNA base pairs to understand genome and the role on non-coding regions in influencing disease phenotype and gene expression. However, the method increases turnaround time, is expensive and complicates the data analysis process. In addition, the unavailability of reimbursement has limited the use of WGS for research. On the other hand, approaches to reduce analytical complexity are likely to drive its adoption for clinical use for informed treatment and prognosis. WES sequences the protein-coding exome, and offers a faster and less expensive option and offers deeper sequencing for better accuracy than WGS. The technique holds limited reimbursement for diagnosis of non-specific genetic conditions. WES is a popular approach for complex clinical diagnostics and selection of suitable treatment.
- Cancer has emerged as one of the most critical health issues faced by the medical world. As per the National Cancer Institute (NCI), more than 13 million people are diagnosed with cancer each year, with relatively higher incidences noted among men. In the developed as well as the developing countries across the world, cancer is the leading cause of mortality, with the proportion comparatively higher in the developing countries. Major cancers, associated with such chronic infectious conditions as cervix and stomach, have become less common with the economic development of several countries. There is a significant rise in the number of individuals affected by rare cancer conditions such as renal cell carcinoma, GBM, lysosomal storage disorders and acute myeloid leukemia among various other orphan indications of cancer in both developed as well as developing countries. The market for breast cancer gene testing is on the rise, given its preventative aspect against the disease. Each year, in the US, about 250,000 women are newly diagnosed with breast cancer, of which about 10% cases occur due to a hereditary, identifiable gene mutation. Common mutations include those in BRCA½ genes, attributed to 16% of all hereditary breast cancers. Incidence of familial breast cancer is increasing considerably in specific ethnic groups including the Ashkenazi Jews. Predictive gene tests, for instance BRACAnalysis test from Myriad Genetics, identify women at risk. Clinically, the test is suggested for high-risk women with breast cancer in their family circles and women already diagnosed with breast cancer, to determine tumor biology. Apart from the U.S. and Europe, densely populated developing countries such as China harbor the largest potential for breast cancer gene testing market.

- Select Competitors (Total 249 Featured) -
  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • Biocartis NV
  • BioRad Laboratories
  • Cepheid Inc.
  • ELITech Group SAS
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Natera, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics AG
  • Roche Molecular Diagnostics, Inc.
  • Thermo Fisher Scientific Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Melanoma - Epidemiology Forecast to 2029

  • $ 3995
  • April 2021
  • 41 pages

Melanoma - Epidemiology Forecast to 2029 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World ...

  • World
  • Cancer
  • Healthcare
  • Industry analysis
  • Cancer Incidence
  • Health Provider Density


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on